$PYPD - PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025 Read the Full Press Release 👉 globenewswire.com/news-release/2…

We are proud and honored to receive the 2025 Therapeutic Solution of the Year! “By addressing one of surgery's most persistent challenges, D-PLEX₁₀₀ delivers better patient outcomes while reducing provider burden” - Bryan Vaughn, Managing Director, BioTech Breakthrough $PYPD

$PYPD PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results Read the Full News Release 👉 globenewswire.com/news-release/2…

Thank you to PolyPid for joining us as a 2026 Gold Sponsor, showing their commitment to improving patient outcomes. Learn more about PolyPid here 👉 polypid.com Interested in partnership with the SIS? Learn more👉 sisna.org/partnerships/

$PYPD PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025 Read the Full News Release 👉 globenewswire.com/news-release/2…

On Dec. 10 at 11:30am ET ROTH Capital will host a #KOL event with Steven D Wexner MD, PhD of MedStar Georgetown to discuss the science and business case for D-PLEX100. Dikla Czaczkes Akselbrad and Ori will be available to answer investors' questions. Registration link 👇 $PYPD

$PYPD PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission Read the Full Press Release 👉 globenewswire.com/news-release/2…

Join us tomorrow (Wednesday) at ROTH Capital's virtual KOL event where internationally recognized colorectal surgeon Steven D. Wexner will discuss the clinical & economic burden of SSIs and the therapeutic potential of D-PLEX₁₀₀. globenewswire.com/news-release/2… $PYPD

$PYPD PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors Read the Full News Release 👉 globenewswire.com/news-release/2…

We are happy to participate in the inaugural Global BioInnovation Forum during #JPMWeek. Jan 13, 2026 | Virtual Register: lnkd.in/g2-PKaju $PYPD

We’re excited to unveil $PYPD new visual brand identity - a look that reflects an important moment in our journey, evolving from a research-driven organization to a commercial-stage company

Proud to see $PYPD included in Bloomberg’s coverage of Israeli Wartime Tech Economy. Here is a link to segment: bit.ly/4biXO1W #RightWhereCareBegins #IsraeliInnovation #Biotech #LifeSciences #HealthcareInnovation

$PYPD PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026 Read the Full News Release 👉 globenewswire.com/news-release/2…

$PYPD Q4 Investor Call is happening today. What a year it has been and more is coming. See our PR to learn more about timing of FDA submission, new branding and new technology platform: investors.polypid.com/news-releases/…

$PYPD PolyPid Announces Participation in Upcoming Investor Conferences Read the Full News Release 👉 globenewswire.com/news-release/2…

Tune in for the latest podcast episode of Smart Money Circle with $PYPD CEO, Dikla Czaczkes Akselbrad. Thank you Adam Sarhan - Host $1 Trillion Dollar Show for hosting us and being a great interviewer 👉 Watch & listen here: youtube.com/watch?v=mX_7wV…

As Marketing Partner for the 38th Annual ROTH Capital Partners Conference, B2i Digital is spotlighting presenting company PolyPid (NASDAQ: $PYPD). PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right

$PYPD PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application Read the Full News Release 👉 globenewswire.com/news-release/2…

$PYPD PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA Read the Full News Release 👉 globenewswire.com/news-release/2…

$PYPD PolyPid to Present New Phase 3 SHIELD II Data Demonstrating DPLEX₁₀₀ Sustained Local Release at ESCMID Global 2026 Read the Full Press Release 👉 globenewswire.com/news-release/2…